Published in Antibiot Khimioter on January 01, 2004
Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing class A beta-lactamase (CTX-M-4): involvement of serine 237 in cephalosporin hydrolysis. Antimicrob Agents Chemother (1998) 3.34
A plasmid-mediated beta-lactamase conferring resistance to cefotaxime in a Salmonella typhimurium clone found in St Petersburg, Russia. J Antimicrob Chemother (1998) 1.79
Misidentification of alpha-hemolytic streptococci by routine tests in clinical practice. Infect Genet Evol (2011) 1.31
Fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Russia: molecular mechanisms implicated. J Antimicrob Chemother (2004) 1.07
In silico screening for tumour-specific expressed sequences in human genome. FEBS Lett (2001) 1.05
Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra. Clin Microbiol Infect (2013) 1.03
[MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones]. Antibiot Khimioter (2007) 1.00
[Genetic determinants of antibacterial resistance among nosocomial Escherichia coli, Klebsiella spp., and Enterobacter spp. isolates collected in Russia within 2003-2007]. Antibiot Khimioter (2010) 0.85
[Genetic environments of bla(CTX-M) genes located on conjugative plasmids of Enterobacteriaceae nosocomial isolates collected in Russia within 2003-2007]. Antibiot Khimioter (2010) 0.82
[Dynamics of Streptococcos pneumoniae antibiotic resistance extension in Moscow in 1998-2003]. Antibiot Khimioter (2004) 0.81
Thin layer alpha-Al2O3:C beta dosemeters for the assessment of current dose rate in teeth due to 90Sr intake, and comparison with electron paramagnetic resonance dosimetry. Radiat Prot Dosimetry (2002) 0.80
[Antibiotic Resistance and Serotype Pattern of Streptococcus pneumoniae Isolated from Children in St. Petersburg in 2010-2013]. Antibiot Khimioter (2015) 0.79
[The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia]. Antibiot Khimioter (2000) 0.79
Correction factors in the EPR dose reconstruction for residents of the Middle and Lower Techa riverside. Health Phys (2001) 0.79
First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia. Clin Microbiol Infect (2012) 0.79
[Development of a PCR-based method for diagnostics of mycoses]. Mol Gen Mikrobiol Virusol (2003) 0.78
[A comparison of the forms of chronic lympholeukemia in relation to the mutational status of the genes of the immunoglobulin variable region]. Ter Arkh (2000) 0.78
[Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections]. Antibiot Khimioter (2003) 0.78
[A new pentanucleotide STR-marker, located in the intron of the ING1 tumor suppressor gene and its allelic polymorphism]. Genetika (2001) 0.77
[Staphylococcal cassette chromosome mec, evolution and genetic lines of methicillin resistant Staphylococcus aureus]. Antibiot Khimioter (2012) 0.77
[Susceptibility of gramnegative carbapenemase-producing bacteria to various group antibiotics]. Antibiot Khimioter (2013) 0.77
[Antibiotic Resistance of MRSA in the Russian Federation]. Antibiot Khimioter (2015) 0.76
[A mass-spectrometric analysis of genetic markers of S. pneumoniae resistance to beta-lactam antibiotics]. Mol Gen Mikrobiol Virusol (2010) 0.76
Effects of Ouabain on Proliferation of Human Endothelial Cells Correlate with Na+,K+-ATPase Activity and Intracellular Ratio of Na+ and K. Biochemistry (Mosc) (2016) 0.76
[Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study]. Antibiot Khimioter (2002) 0.76
[Epidemiology of mycosis and pathogen susceptibility to antimycotics]. Antibiot Khimioter (2007) 0.75
[Ceftriaxone: whether there is future for it?]. Antibiot Khimioter (2006) 0.75
[Transcription map of the 13q14 region, frequently deleted in B-cell chronic lymphocytic leukemia patients]. Genetika (2001) 0.75
[Genomic organization of the suppressor gene for tumor growth ING1]. Mol Biol (Mosk) (2000) 0.75
[Indices of lipid metabolism in children with dysmetabolic nephropathy undergoing balneotherapy with nitric-silicon thermal water]. Vopr Kurortol Fizioter Lech Fiz Kult (2008) 0.75
[Structural-functional characteristics of the 13q14 region of the human genome in the search for potential tumor suppressor genes]. Mol Biol (Mosk) (2004) 0.75
[Levofloxacin and other antibacterial drugs]. Antibiot Khimioter (2006) 0.75
[Current problems of diagnosis and treatment of tuberculosis]. Antibiot Khimioter (1999) 0.75
[Ciprofloxacin and antibacterial therapy of respiratory tract infections]. Antibiot Khimioter (2006) 0.75
[Dynamics of beta-lactams resistance distribution in Streptococcus pneumoniae and its clinical significance]. Antibiot Khimioter (2010) 0.75
[Population pattern of pneumococci with lower susceptibility to penicillin and prospects of antipneumococcal vaccination to control antibiotic resistance distribution]. Antibiot Khimioter (2011) 0.75
[Resistance epidemiology of gramnegative nonfermenting pathogens of nosocomial infections in intensive care units and surgical departments]. Antibiot Khimioter (2006) 0.75
[Antimicrobial prophylaxis of surgical wound infections]. Antibiot Khimioter (2005) 0.75
[Antimicrobial susceptibility and molecular mechanisms of resistance to beta-lactams of gram-negative microorganisms--causative agents of nosocomial infections]. Zh Mikrobiol Epidemiol Immunobiol (2007) 0.75
[Ciprofloxacin and therapy of urinary tract infections, including those due to Staphylococcus saprophyticus]. Antibiot Khimioter (2006) 0.75
[Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis]. Antibiot Khimioter (2006) 0.75
[Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm']. Antibiot Khimioter (2007) 0.75
[Search for transcribed segments in the region of q14.3 of human chromosome 13 in silico]. Genetika (2004) 0.75
[Practical approaches to the treatment of bacterial meningitis]. Antibiot Khimioter (2007) 0.75
[Acute rheumatic fever and Streptococcus group A tonsillitis: the current status of the problem and the questions of antibiotic therapy]. Antibiot Khimioter (2000) 0.75
[Shiga toxin production by Escherichia coli strains and antibiotics]. Antibiot Khimioter (2001) 0.75
[Imipenem: 30-year experience in therapy]. Antibiot Khimioter (2013) 0.75
[Haemophilus influenzae antibiotic resistant strains isolated in Moscow in 2002-2004]. Antibiot Khimioter (2004) 0.75
[Clinicomicrobiological monitoring of patients with exacerbation of chronic bronchitis treated with antibacterial drugs]. Ter Arkh (2006) 0.75
[Molecular characteristic of methicillin-resistant Staphylococcus aureus strains isolated in Moscow clinics]. Mol Gen Mikrobiol Virusol (2010) 0.75
[THE SPECIES COMPOSITION OF AGENTS OF COMMUNITY-ACQUIRED INFECTIONS OF URINARY TRACTS AND SENSITIVITY OF MAIN UROPATHOGENS TO ANTIBACTERIAL PREPARATIONS IN MOSCOW IN 2013]. Klin Lab Diagn (2015) 0.75
[A procedure for layer therapeutic-and-tectonic keratoplasty in corneal thinning]. Vestn Oftalmol (2005) 0.75
[Characteristics and clinical value of extended-spectrum beta-lactamases]. Antibiot Khimioter (2003) 0.75
[The future of clinical microbiology as a laboratory service]. Antibiot Khimioter (1999) 0.75
[Prospects for control of the occurence of antibiotic resistance]. Antibiot Khimioter (1998) 0.75
[What is the future of antibacterial therapy?]. Antibiot Khimioter (1999) 0.75
[A comparative evaluation of the pharmacokinetics of different forms of benzathine benzylpenicillin]. Antibiot Khimioter (2000) 0.75
[Prospects of development of drugs for therapy of gram-positive bacterial infections]. Antibiot Khimioter (2000) 0.75
[In the commission on antibiotic policy]. Antibiot Khimioter (1998) 0.75
[Discovery of Genetic Markers of Resistance to β-Lactams in Gramnegative Microorganisms by PCR Diagnosis]. Antibiot Khimioter (2015) 0.75
[Fundamental and applied aspects of comparative genomics of vertebrates]. Genetika (2003) 0.75
[Peat peloids from the Bichevskoye deposits of the Khabarovsk region and their physicochemical characteristics]. Vopr Kurortol Fizioter Lech Fiz Kult (2014) 0.75
[Staphylococci and vancomycin--confrontation trends]. Antibiot Khimioter (2003) 0.75
[Structural Polymorphism of Genome Islands Encoding Resistance to Beta-Lactams in Coagulase-Negative Staphylococci Isolated at Hospitals of the Russian Federation]. Antibiot Khimioter (2015) 0.75
[90-year anniversary of the Kuldur health resort]. Vopr Kurortol Fizioter Lech Fiz Kult (2014) 0.75
[Clinical and economic expedience of ertapenem therapy of complicated urinary tract infection]. Antibiot Khimioter (2011) 0.75
[Differentiation of α-hemolytic Streptococci by direct mass spectrometry profiling]. Bioorg Khim (2011) 0.75
[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children]. Zh Mikrobiol Epidemiol Immunobiol (1999) 0.75
[Clinical strains of Burkholderia cepacia: characteristic and detection of the components in the quorum sensing regulatory system]. Mol Gen Mikrobiol Virusol (2003) 0.75
[Biological characteristic of the main pathogens in purulent bacterial meningitis]. Antibiot Khimioter (2002) 0.75
[Efficient antimicrobial chemotherapy for skin and soft tissue infections]. Antibiot Khimioter (2003) 0.75
[The possibility of using chloride sodium, magnesium, and calcium-rich mineral water for the treatment of children with dysmetabolic nephropathy]. Vopr Kurortol Fizioter Lech Fiz Kult (2008) 0.75
[Nosocomial infections: epidemiology, pathogenesis, etiology, antibacterial therapy, and prophylaxis]. Antibiot Khimioter (2005) 0.75
[Etiology and microbiological diagnosis of nosocomial pneumonia in newborns]. Antibiot Khimioter (2001) 0.75
[Etiology of severe hospital infections in intensive care units and antibiotic resistance of pathogens]. Antibiot Khimioter (2005) 0.75
[Cross and associated antibiotic resistance of gramnegative bacteria of the family Enterobacteriaceae resistant to the 3rd generation cephalosporins]. Antibiot Khimioter (2008) 0.75
[Community-acquired pneumonia: standards for empirical antibacterial therapy]. Antibiot Khimioter (1999) 0.75
[Resistance of Russian isolates of Neisseria gonorrhoeae to fluoroquinolones]. Mol Gen Mikrobiol Virusol (2005) 0.75
[Genotypic emm-typing of streptococcal cultures, group A, isolated from patients with different clinical manifestations of streptococcal infection in Moscow]. Zh Mikrobiol Epidemiol Immunobiol (2005) 0.75
[Hospital infections caused by Pseudomonas aeruginosa. Significance in intensive therapy]. Anesteziol Reanimatol (1999) 0.75
[Annenskie mineral waters: the history of discovery (the 150th anniversary of the balneotherapeutic centre spa "Annenskie waters")]. Vopr Kurortol Fizioter Lech Fiz Kult (2015) 0.75
[Evaluation of the usefulness of three collections of bacteriophages for typing methicillin-resistant Staphylococcus aureus, isolated in Moscow hospitals]. Zh Mikrobiol Epidemiol Immunobiol (2003) 0.75
[Aminopenicillins and beta-lactamase inhibitors]. Antibiot Khimioter (2006) 0.75
[Candiduria: problems of diagnosis and therapy]. Antibiot Khimioter (2005) 0.75
Multibeam interferometric methods for measuring very small periodic displacements. Appl Opt (1989) 0.75
[Purulent meningitis in newborn infants (its etiology, pathogenesis, clinical picture, diagnosis, treatment)]. Antibiot Khimioter (2000) 0.75
[Treatment of intestinal dysbacteriosis in children with diabetes mellitus]. Antibiot Khimioter (1999) 0.75
[ A case of primary hyperparathyroidism]. Sov Med (1990) 0.75
[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin]. Antibiot Khimioter (2013) 0.75
[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods]. Antibiot Khimioter (2007) 0.75
[Antibiotic Resistance of Coagulase-Negative Staphylococci Isolated at Hospitals of St. Petersburg and Moscow]. Antibiot Khimioter (2015) 0.75
[Effectiveness of present-day therapy of purulent lesions of the cornea]. Vestn Oftalmol (2003) 0.75
[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. Antibiot Khimioter (2005) 0.75
[A mode of penetrating therapeutic keratoplasty in purulent keratitis]. Vestn Oftalmol (2005) 0.75
[Protective properties of doxycycline, rifampicin and sisomycin in experimental pulmonary tularemia of albino mice]. Antibiot Khimioter (1998) 0.75
[Extended release fluoroquinolone formulations]. Antibiot Khimioter (2004) 0.75
[Synthesis and antibacterial activity of new polyfluoro-1,3,5-oxadiazines]. Antibiot Khimioter (2005) 0.75